BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Telotristat etiprate: Phase II data

Top-line data from a double-blind, placebo-controlled, U.S. Phase II trial in 23 patients with refractory carcinoid syndrome showed that 5 patients treated with once-daily LX1032 for 28 days achieved a clinical response defined as a reduction of >=30% in the number of bowel movements per day for >=2...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >